TWI781405B - 使用磺醯胺化合物與免疫調節劑之癌併用療法 - Google Patents

使用磺醯胺化合物與免疫調節劑之癌併用療法 Download PDF

Info

Publication number
TWI781405B
TWI781405B TW109117778A TW109117778A TWI781405B TW I781405 B TWI781405 B TW I781405B TW 109117778 A TW109117778 A TW 109117778A TW 109117778 A TW109117778 A TW 109117778A TW I781405 B TWI781405 B TW I781405B
Authority
TW
Taiwan
Prior art keywords
group
atom
ring
hydrogen atom
carbon atoms
Prior art date
Application number
TW109117778A
Other languages
English (en)
Chinese (zh)
Other versions
TW202110442A (zh
Inventor
上野裕之
月岡清夏
Original Assignee
日商大鵬藥品工業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商大鵬藥品工業股份有限公司 filed Critical 日商大鵬藥品工業股份有限公司
Publication of TW202110442A publication Critical patent/TW202110442A/zh
Application granted granted Critical
Publication of TWI781405B publication Critical patent/TWI781405B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW109117778A 2019-05-29 2020-05-28 使用磺醯胺化合物與免疫調節劑之癌併用療法 TWI781405B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019-100136 2019-05-29
JP2019100136 2019-05-29

Publications (2)

Publication Number Publication Date
TW202110442A TW202110442A (zh) 2021-03-16
TWI781405B true TWI781405B (zh) 2022-10-21

Family

ID=73553795

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109117778A TWI781405B (zh) 2019-05-29 2020-05-28 使用磺醯胺化合物與免疫調節劑之癌併用療法

Country Status (8)

Country Link
US (1) US20220226291A1 (https=)
EP (1) EP3978017A4 (https=)
JP (1) JP7179174B2 (https=)
KR (1) KR102748684B1 (https=)
AU (1) AU2020283299B2 (https=)
MA (1) MA56065A (https=)
TW (1) TWI781405B (https=)
WO (1) WO2020241749A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240158383A1 (en) * 2021-03-02 2024-05-16 Boundless Bio, Inc. Ribonucleotide reductase (rnr) inhibitors and uses thereof
IL311458A (en) * 2021-09-17 2024-05-01 Boundless Bio Inc Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof
EP4402134A4 (en) * 2021-09-17 2025-10-15 Boundless Bio Inc SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND THEIR USES
JP2025531147A (ja) * 2022-09-13 2025-09-19 バウンドレス バイオ，インク． 環状スルホンアミドリボヌクレオチドレダクターゼ（ｒｎｒ）阻害剤およびその使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201800395A (zh) * 2016-05-31 2018-01-01 Taiho Pharmaceutical Co Ltd 磺醯胺化合物或其鹽

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
AU2015203322B2 (en) * 2009-07-20 2016-09-29 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
EP3099717B1 (en) * 2014-01-31 2019-03-27 Novartis AG Antibody molecules to tim-3 and uses thereof
US20150259420A1 (en) * 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
US11612653B2 (en) * 2016-01-08 2023-03-28 Taiho Pharmaceutical Co., Ltd. Anti-tumor agent containing immunomodulator, and antitumor effect potentiator
JP7023690B2 (ja) 2017-12-06 2022-02-22 株式会社東芝 道路維持管理システム、道路維持管理方法及びコンピュータプログラム

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201800395A (zh) * 2016-05-31 2018-01-01 Taiho Pharmaceutical Co Ltd 磺醯胺化合物或其鹽

Also Published As

Publication number Publication date
EP3978017A1 (en) 2022-04-06
MA56065A (fr) 2022-04-06
KR20220015430A (ko) 2022-02-08
US20220226291A1 (en) 2022-07-21
TW202110442A (zh) 2021-03-16
KR102748684B1 (ko) 2025-01-02
AU2020283299B2 (en) 2024-08-01
JPWO2020241749A1 (https=) 2020-12-03
WO2020241749A1 (ja) 2020-12-03
EP3978017A4 (en) 2023-06-28
JP7179174B2 (ja) 2022-11-28
AU2020283299A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
TWI781405B (zh) 使用磺醯胺化合物與免疫調節劑之癌併用療法
JP6885390B2 (ja) Ａｘｌ阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬
TW202019900A (zh) Ptpn11抑制劑
WO2018049008A1 (en) Dash inhibitors, and uses related thereto
US20250170108A1 (en) Chemotherapy for cancer using azabicyclo compound
EP3781162A1 (en) Ep4 inhibitors and use thereof
TWI829329B (zh) 組蛋白去乙醯化酶6和熱休克蛋白90之雙重抑制劑
EP4209216A1 (en) Pharmaceutical composition for treating tumors
WO2024173761A1 (en) Combinations comprising mek inhibitors for use in the treatment of cancer
JP2021513512A (ja) 癌または炎症性疾患の治療のためのヘテロ二環式カルボキシ酸
US20230201161A1 (en) Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment
TWI649082B (zh) 使用奧諾拉（ａｕｒｏｒａ）激酶抑制劑治療癌症的方法
RU2820817C2 (ru) Комбинированное лечение злокачественного новообразования с использованием сульфонамидного соединения и иммунорегулятора
TW202114659A (zh) 用於癌症治療之含ｈｄａｃ抑制劑、ｃｔｌａ—４抑制劑及ｐｄ—１抑制劑或ｐｄ—ｌ１抑制劑之組合
JP7816164B2 (ja) Ｅｐ４拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療
WO2016194390A1 (en) Pharmaceutical composition for use in the treatment of cancer
JP2026067904A (ja) Ｅｐ４拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療
BR112019028226B1 (pt) Agente antitumoral que compreende um composto azabiciclo em combinação com um regulador da molécula de checkpoint imunológico, agente potencializador de efeito antitumoral para o dito regulador, imunoestimulante e usos dos ditos composto e regulador para tratar câncer
BR122025010361A2 (pt) Agente antitumoral compreendendo um composto azabiciclo em combinação com um regulador da molécula de checkpoint imunológico, agente potencializador de efeito antitumoral para o dito regulador, imunoestimulante e usos dos ditos composto e regulador
HK40020604A (en) Chemotherapy for cancer using azabicyclo compound

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent